Mechanistically, mutant p53 binds to and activates SREBP, crucial transcription factors that regulate transcription of several enzymes involved in the mevalonate pathway, leading to enhanced prenylation of proteins associated with cancer progression and activation of prenylated proteins in breast cancer cells; hence, inhibition of protein prenylation by statins leads to reduced malignancy of human breast cancer cells (16). Here, TP53 is linked to breast carcinoma.